Rheumatology is branch of medicine that deals with the diagnosis and treatment of disorders of connective tissues and joints, many of which are now known to be immune mediated conditions.
Anti-TNF biosimilars: Exploring the possibilities
Tune in to our new podcast series, hosted by Professor Peter Taylor. Hear about the factors influencing choice of biological DMARDs and about the manufacture and regulation of biosimilars and their impact on clinical practice.
Rheumatic diseases can be caused by trauma, heredity, genetic abnormality, autoimmune disease, or another underlying condition such as cancer. There are more than 150 different types of rheumatic disorders, including arthritis, rheumatoid and osteoarthritis, gout and lupus.
Related news and insights
As part of its longstanding commitment to patients in rheumatology, UCB, a global biopharmaceutical company, is sponsoring an expert-led, multi-stakeholder programme called Rheumacensus. The programme aims to identify key challenges in the current care pathways of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) across Europe, and reach consensus on potential improvements
UCB, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of certolizumab pegol and adalimumab in patients with rheumatoid arthritis (RA) with high rheumatoid factor (RF) levels . The data are being presented at the American College of Rheumatology (ACR) Convergence 2023 in San Diego, U.S., November 10–15.
- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry